Amicus Therapeutics has expanded its research and development (R&D) alliance with the Perelman School of Medicine at the University of Pennsylvania (Penn).
Researchers from the University of Pennsylvania (Penn) Abramson Cancer Center have announced findings from the ADMIRAL trial of gilteritinib in patients with relapsed or refractory acute myeloid leukaemia (AML) with a mutation in the Fms-like tyrosine kin